Clinical trials: Thromboses, Venous
Atrial Fibrillation, Venous Thromboembolism
Edoxaban Management in Diagnostic and Therapeutic Procedures
Patients receiving Novel Oral Anticoagulation (NOACs) undergo diagnostic and therapeutic procedures at a rate of 10% per year. Short half-lives and rapid onset of action allow for short periods of NOAC interruption without…
- Trial name
- EMIT-AF/VTE (NCT02950168)
- Testing
- Edoxaban
- Volunteers
- 1,197 people
- Sponsor
- Daiichi Sankyo
Venous Thrombosis
Switching Study From Warfarin to Rivaroxaban
The study objective is to investigate the pharmacodynamics (effects of a drug product) when switching the treatment from warfarin to rivaroxaban.
- Trial name
- NCT01507051
- Testing
- Warfarin (Coumadin), Rivaroxaban (Xarelto, BAY59-7939), Vitamin K (Konakion)
- Where
- 2 sites in Germany
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Bayer
Venous Thromboembolism
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility
The primary objective was to compare the efficacy of once daily [q.d] subcutaneous [s.c.] injections of Semuloparin sodium (AVE5026) with q.d. s.c.
- Trial name
- SAVE-VEMED (NCT00714597)
- Testing
- Semuloparin sodium, Enoxaparin sodium
- Where
- 22 sites in United States, Australia and 20 more
- Volunteers
- 421 people
- Sponsor
- Sanofi
Venous Thromboembolism
Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients
Three month treatment of acute VTE with Fragmin in pediatric cancer patients
- Trial name
- NCT00952380
- Testing
- dalteparin
- Where
- 26 sites in United States, Norway and 3 more
- Volunteers
- 38 people
- Sponsor
- Pfizer
Branch Retinal Vein Occlusion
601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)
To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to macular edema secondary to BRVO
- Trial name
- NCT04667897
- Testing
- 601 1.25mg, Ranibizuman 0.5 mg
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Phenprocoumon for the first…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947959
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Standard of care
- Where
- Germany
- Volunteers
- 665,533 people
- Sponsor
- Bayer
Venous Thromboembolism
Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty
The purpose of this study is: To assess the safety and efficacy profile of ISIS-FXIRx, including incidence of bleeding and VTE, in patients undergoing total knee arthroplasty.
- Trial name
- NCT01713361
- Testing
- ISIS-FXIRx Dose #2, ISIS-FXIRx Dose #3, Enoxaparin
- Where
- 21 sites in Bulgaria, Canada and 3 more
- Volunteers
- 315 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Thrombosis
Pediatric Catheter-related Thrombosis Imaging Study
This protocol will serve as a pilot study to determine the validity and feasibility of contrast enhanced magnetic resonance imaging (MRI) without and with contrast and/or ultrasound (US) for detection of catheter related deep…
- Trial name
- AESOP (NCT01137578)
- Testing
- Ultrasound, Magnetic Resonance Imaging with Contrast, Magnetic Resonance Imaging without Contrast
- Where
- 26 sites in United States, Argentina and 7 more
- Volunteers
- 151 people
- Sponsor
- Bristol-Myers Squibb
Venous Thrombosis
Enoxaparin in Acute Venous Thromboembolic Disease
Study objectives : To evaluate the efficacy/safety profile of enoxaparin once a day treatment in acute venous thromboembolic disease.
- Trial name
- NCT00265993
- Testing
- enoxaparin
- Where
- Turkey (Türkiye)
- Volunteers
- 251 people
- Sponsor
- Sanofi
Venous Thromboembolism
Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement
The main purpose of this study is to determine if an investigational medication called SelK2 works in preventing a condition called "venous thromboembolism" (VTE) in patients having a total knee replacement.
- Trial name
- COURSE (NCT03812328)
- Testing
- SelK2, Enoxaparin
- Where
- 21 sites in Bulgaria, Latvia and 3 more
- Volunteers
- 207 people
- Sponsor
- Tetherex Pharmaceuticals Corporation
Deep Venous Thrombosis
Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)
This study will evaluate the safety profile of GMI-1271 and its effect on thrombus resolution in patients with distal calf vein Deep Venous Thrombosis (DVT).
- Trial name
- NCT02744833
- Testing
- GMI-1271, Enoxaparin Sodium (Lovenox®)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- GlycoMimetics Incorporated
Venous Thromboembolism
Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
This study will evaluate if extended therapy with oral rivaroxaban can prevent blood clots in the leg and lung that can occur with patients hospitalized for acute medical illness, and compare these results with those of the…
- Trial name
- MAGELLAN (NCT00571649)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
- Where
- 676 sites in United States, Argentina and 51 more
- Volunteers
- 8,101 people
- Sponsor
- Bayer
Thrombosis, Venous
Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common post-operative complication.
- Trial name
- NCT01444612
- Testing
- dalteparin, enoxaparin, fondaparinux
- Volunteers
- 4,068 people
- Sponsor
- GlaxoSmithKline
Retinopathy, Retinal Vein Occlusion
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
The objective of this study is to evaluate the safety and image quality of the investigational dye, MB-102, compared to the control dye (fluorescein sodium) in healthy and diseased eyes using fluorescent angiography for retinal…
- Conditions
- Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration
- Trial name
- NCT04008121
- Testing
- Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- MediBeacon
Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety
This is a Phase IV, randomized, open-label, active-controlled, 2-arm, multicenter study. The primary objective was assessed by the difference in the mean number of ranibizumab injections applied up to Month 11 between the 2…
- Trial name
- ZIPANGU (NCT02953938)
- Testing
- Ranibizumab, Grid&Direct short pulse laser photocoagulation
- Where
- 7 sites in Japan
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Atrial Fibrillation, Deep Vein Thrombosis
Association Between Genetic Variant Scores and Warfarin Effect
Study objective is to determine whether there is an association between genetic variant risk scores and clinical outcomes (percent time in therapeutic range, time to reach therapeutic international normalized ratio (INR), INR ≥…
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Intracardiac Thrombus, Pulmonary Embolism
- Trial name
- AWARE1 (NCT03894878)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Cipherome, Inc.
Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO)
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada
The primary objective of this study is to measure physician knowledge and understanding of the key safety information contained in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the…
- Conditions
- Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO), Diabetic Macular Edema (DME)
- Trial name
- NCT02585401
- Testing
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
- Where
- Canada
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Bayer
Thrombosis, Cerebral Ischemia
Study of Safety and Biomarker Efficacy of TS23 in Healthy Volunteer
This study is designed to determine the safety, pharmacokinetics and pharmacodynamics of a single intravenous dose of TS23 in healthy adults.
- Conditions
- Thrombosis, Cerebral Ischemia, Venous Thrombosis, Pulmonary Embolism
- Trial name
- TS23Phase1a (NCT03001544)
- Testing
- TS23
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Translational Sciences, Inc.
Treatment of Venous Thromboembolism in Cancer Patients, Venous Thromboembolism
An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism)
This is an observational study in which patient data from the past on venous thromboembolism (VTE) in people with cancer is studied. In observational studies, only observations are made without specified advice or interventions.
- Conditions
- Treatment of Venous Thromboembolism in Cancer Patients, Venous Thromboembolism, Cancer
- Trial name
- H2H-OSCAR-US (NCT05461807)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban
- Where
- Germany
- Volunteers
- 2,437 people
- Sponsor
- Bayer
Venous Thrombosis
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study
This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic DVT without…
- Trial name
- NCT00440193
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin followed by VKA
- Where
- 324 sites in United States, Australia and 32 more
- Volunteers
- 3,449 people
- Sponsor
- Bayer